Jaguar Health Implements Reverse Stock Split
News related to:Jaguar Health, Inc · 1 min read
Jaguar Health, Inc., a company focused on developing prescription drugs derived from plants for gastrointestinal diseases, announced a significant corporate action on September 15, 2026. The company will implement a reverse stock split, reducing the number of shares outstanding to better align with Nasdaq's listing standards.
Effective on September 17, 2026, the reverse stock split will be executed at a ratio of 1-for-15. This means that every 15 shares of Jaguar Health common stock will be reclassified into one share. The company's common stock will begin trading on a split-adjusted basis from the opening of the market on the effective date. The new CUSIP number for the company's common stock following the reverse stock split is 47010C854.
The decision to proceed with the reverse stock split was approved at the company's April 2026 Special Meeting of Stockholders. The proposal was detailed in the Company's definitive proxy statement filed with the Securities and Exchange Commission on March 24, 2026. Stockholders can access this document on the SEC's website or on Jaguar Health's corporate website.
The reverse stock split is part of Jaguar Health's ongoing efforts to ensure compliance with Nasdaq's listing requirements. No fractional shares will be issued as a result of the reverse stock split. Instead, stockholders who would otherwise receive fractional shares will receive a cash payment in lieu thereof.
Equiniti Trust Company, LLC, has been designated as the exchange agent for the reverse stock split. Instructions will be sent to stockholders of record who hold stock certificates. Stockholders who hold their shares in brokerage accounts or "street name" are not required to take any action to effect the exchange of their shares.
Jaguar Health, Inc., continues to develop novel proprietary prescription drugs sustainably derived from plants for people with complex gastrointestinal disease states. The company's family of companies, including Napo Pharmaceuticals, Inc., Napo Therapeutics S.p.A., and Magdalena Biosciences, are dedicated to the development and commercialization of innovative treatments for rare and orphan gastrointestinal disorders.